Alaunos Therapeutics:Aln1003治疗组动物经体脂校正后HOMA-IR评分显著降低

美股速递
May 18

Alaunos Therapeutics公司公布的研究数据显示,在经体脂调整后,接受其候选疗法Aln1003治疗的实验动物,其胰岛素抵抗稳态模型评估(HOMA-IR)评分出现显著下降。这一结果表明Aln1003在改善胰岛素敏感性方面可能具有潜在效用。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10